AMI’s annual Specialty Hub Service Providers Report provides comprehensive business intelligence on more than 70 companies
Arcutis recently announced that ZORYVE (roflumilast) cream 0.3% for topical use is now available in the United States for the treatment of plaque psoriasis in people aged 12 and older
Phil, Inc. is a software therapy deployment platform, offering pharmaceutical manufacturers a modern alternative to traditional access, affordability and distribution options
A number of innovative companies have entered the increasingly competitive traditional specialty pharmaceutical Hub services market
By addressing patient access challenges using online technologies, as opposed to traditional call-center models, Phil Inc. partners with pharmaceutical manufacturers to deliver pioneering digital access to Specialty and Specialty-Lite therapies.